Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

986 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
Nicoletti F, Di Marco R, Patti F, Zaccone P, L'Episcopo MR, Reggio E, Xiang M, Nicoletti A, Reggio A. Nicoletti F, et al. Among authors: nicoletti a. Cytokine. 2000 Jun;12(6):682-7. doi: 10.1006/cyto.1999.0616. Cytokine. 2000. PMID: 10843745
Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b).
Nicoletti F, Di Marco R, Patti F, Reggio E, Nicoletti A, Zaccone P, Stivala F, Meroni PL, Reggio A. Nicoletti F, et al. Among authors: nicoletti a. Clin Exp Immunol. 1998 Jul;113(1):96-9. doi: 10.1046/j.1365-2249.1998.00604.x. Clin Exp Immunol. 1998. PMID: 9697990 Free PMC article. Clinical Trial.
The antiinflammatory cytokine interleukin-13 is not detectable in the circulation of multiple sclerosis patients and is not inducible by interferon-beta1b treatment, that neither modifies its ex vivo secretion from peripheral blood mononuclear cells.
Nicoletti F, Di Marco R, Patti F, Nicoletti A, Leonardi C, Reggio E, Meroni P, Reggio A. Nicoletti F, et al. Among authors: nicoletti a. Autoimmunity. 2000 Dec;32(4):265-70. doi: 10.3109/08916930008994100. Autoimmunity. 2000. PMID: 11191285
The effect of cefepime on some immune parameters in vitro: lack of interference with mitogen-induced lymphoproliferation, immunoglobulin synthesis, IFN-gamma and IL-2 secretion and IL-2 receptor expression.
Di Marco R, Carrabba I, Cavallaro V, Zaccone P, Stazzone C, Franco S, Cocuzza C, Nicoletti G, Nicoletti F. Di Marco R, et al. Among authors: nicoletti g, nicoletti f. J Chemother. 1993 Oct;5(5):297-301. doi: 10.1080/1120009x.1993.11739248. J Chemother. 1993. PMID: 8106902
986 results